Recombinant Human Asialoglycoprotein receptor 2 (ASGR2)

What is the molecular structure of human ASGR2?

Recombinant Human ASGR2 is a single-pass type II transmembrane protein and member of the C-type lectin receptor family with an approximate molecular weight of 48 kDa. The mature protein consists of three distinct domains: a short cytoplasmic domain (5 amino acids), a transmembrane segment (21 amino acids), and an extracellular domain (ECD) of 232 amino acids. Within the ECD, human ASGR2 shares 66% and 62% amino acid sequence identity with mouse and rat ASGR2, respectively . The protein is expressed primarily in hepatocytes but has also been detected in human peripheral blood monocytes .

How does ASGR2 function in the asialoglycoprotein receptor complex?

ASGR2 functions as a critical component of the asialoglycoprotein receptor (ASGPR), also known as the Ashwell receptor, forming a heterooligomeric complex with ASGR1. This receptor complex mediates the removal of potentially hazardous glycoconjugates from blood circulation in both health and disease states . The receptor recognizes terminal galactose residues on desialylated glycoproteins, facilitating their endocytosis and subsequent lysosomal degradation. ASGR2 exhibits specific binding activity toward von Willebrand Factor (vWF) with an ED50 of 0.15-0.9 μg/mL, which is instrumental in regulating vWF and platelet homeostasis . This endocytic clearance mechanism represents a critical physiological process for maintaining glycoprotein homeostasis and preventing potential toxicity from circulating desialylated proteins.

What alternative splicing variants of ASGR2 have been identified?

ASGR2 undergoes complex alternative splicing, generating five distinct transcripts (designated TH2′, T1, T2, T3, and T4) that encode four different protein isoforms (a-d). The splicing variants differ in their specific domain structures, particularly with regard to in-frame deletions . Notably, isoforms a and c contain a critical 5-amino acid sequence that serves as a proteolysis cleavage signal located near the junction between the transmembrane domain and the carbohydrate recognition domain (CRD). This signal sequence enables proteolytic cleavage resulting in secretion of the CRD as a soluble protein. In contrast, isoforms b and d lack this signal sequence and consequently remain membrane-bound, where they can oligomerize with ASGR1 isoform a to form the native ASGPR complex at the cell surface . This diversity in splice variants likely contributes to the functional versatility of ASGR2 in different cellular contexts.

What are the optimal conditions for detecting ASGR2 expression in different cell types?

The detection of ASGR2 expression requires carefully optimized methodologies depending on the cell type being investigated. For hepatic cell lines such as HepG2 (which express high levels of the Ashwell receptor and serve as excellent positive controls), standard protocols involve cell culture at 37°C in water-saturated air (95%, v/v) with CO2 (5%, v/v) . When investigating non-hepatic cells like peripheral blood monocytes, where expression levels may be lower, nested PCR approaches have proven more effective.

The optimal protocol involves:

• Initial RNA extraction using standard techniques

• Two-round nested PCR with carefully designed primers:

  • First round: 94°C for 30s; 60°C for 30s; 72°C for 1min 30s (30 cycles)

  • Second round: 94°C for 30s; 60°C for 30s; 72°C for 1min (30 cycles)

• Analysis via either:

  • 2% agarose gel electrophoresis with ethidium bromide staining

  • 5% polyacrylamide gel electrophoresis with silver staining

For quantitative assessment, real-time PCR using LightCycler FastStart DNA Master SYBR Green I with 3 mmol/L MgCl2 final concentration and reaction conditions of 94°C for 10 min followed by 55 cycles of 94°C for 10s; 64°C for 5s; 72°C for 10s provides reliable results . This methodological approach enables detection of even low-abundance ASGR2 transcripts in non-hepatic tissues.

How can recombinant ASGR2 protein be effectively produced and purified for research applications?

Recombinant ASGR2 protein production typically utilizes an Fc chimera approach to enhance stability and facilitate purification. The protein is commonly expressed as a chimeric construct consisting of the extracellular domain of ASGR2 fused to the Fc region of human IgG1. Based on the available commercial constructs, the optimal design includes:

This construct yields a recombinant protein that appears as bands of 62-81 kDa under reducing conditions and 120-160 kDa under non-reducing conditions when analyzed by SDS-PAGE and Coomassie Blue staining . This approach ensures proper protein folding and biological activity, as evidenced by the ability of the recombinant protein to bind human plasma von Willebrand Factor with high affinity (ED50 of 0.15-0.9 μg/mL) . The purification strategy typically employs affinity chromatography targeting the Fc region, which yields a highly pure preparation suitable for downstream research applications.

What experimental controls are essential when studying ASGR2 binding interactions?

When investigating ASGR2 binding interactions, particularly with von Willebrand Factor (vWF), several essential controls must be incorporated to ensure experimental validity:

• Positive control cell line: HepG2 cells, which express high levels of the Ashwell receptor, should be included as a reference standard for ASGR2 expression and binding activity .

• Negative binding controls: Non-sialylated glycoproteins should demonstrate no or minimal binding to confirm specificity of the interaction.

• Competitive inhibition: Pre-incubation with known ligands (such as asialofetuin) should inhibit binding in a dose-dependent manner.

• Cross-species reactivity assessment: When using recombinant mouse ASGR2 Fc chimera proteins, researchers should note the differences in binding kinetics compared to human ASGR2. Mouse ASGR2 binds human plasma von Willebrand Factor with an ED50 of 0.05-0.6 μg/mL , compared to human ASGR2's ED50 of 0.15-0.9 μg/mL , indicating potential species-specific differences in binding affinities.

• Structure-function correlation: Binding studies should evaluate both membrane-bound isoforms (b and d) and soluble forms (cleaved from isoforms a and c) to determine the functional significance of the proteolytic cleavage signal present in specific splice variants .

These controls ensure that the observed binding interactions are specific, physiologically relevant, and accurately interpreted within the context of ASGR2's biological function.

How does ASGR2 contribute to platelet and von Willebrand Factor homeostasis during sepsis?

ASGR2, as part of the Ashwell receptor complex, plays a critical role in platelet and von Willebrand Factor (vWF) homeostasis, particularly during sepsis. Research has revealed that ASGPR (the Ashwell receptor complex containing both ASGR1 and ASGR2) modulates platelet homeostasis through a two-step mechanism involving:

• Initial desialylation of platelets during sepsis caused by pathogens like S. pneumoniae

• Subsequent clearance of these desialylated platelets by the Ashwell receptor

Interestingly, while ASGR1 can participate in plasma vWF clearance independently of sialylation status and septic conditions, ASGR2 demonstrates increased colocalization with plasma vWF specifically in ASGR1-deficient mice . This suggests a compensatory mechanism and distinct binding properties between the two receptor components.

Experimental data demonstrates that both recombinant human and mouse ASGR2 Fc chimera proteins exhibit high-affinity binding to human plasma vWF, with ED50 values of 0.15-0.9 μg/mL and 0.05-0.6 μg/mL respectively . This binding affinity forms the molecular basis for ASGR2's role in regulating vWF levels during inflammatory states, potentially serving as a protective mechanism to prevent excessive coagulation during sepsis-induced inflammation.

What is the potential significance of ASGR2 expression in non-hepatic tissues?

While ASGR2 has traditionally been considered a hepatic-specific protein, research has demonstrated its expression in extra-hepatic tissues, most notably in peripheral blood monocytes . This discovery challenges the conventional understanding of ASGR2 as exclusively hepatic and opens new avenues for investigating its functions in immune regulation and systemic glycoprotein homeostasis.

When investigating ASGR2 expression in monocytes, researchers found correctly spliced transcript variants encoding different isoforms, suggesting functional relevance rather than aberrant expression . The presence of ASGR2 in circulating monocytes may enable these cells to:

• Participate in the clearance of desialylated glycoproteins in the bloodstream

• Contribute to immune surveillance by recognizing altered glycosylation patterns on pathogenic particles

• Potentially regulate monocyte-platelet interactions during inflammatory responses

This non-hepatic expression pattern suggests that ASGR2 may have broader physiological roles than previously recognized, particularly in immune function and the surveillance of glycosylation status in circulation. The methodological approach to studying these extra-hepatic functions requires careful optimization of detection methods, as expression levels may be substantially lower than in hepatocytes.

How can ASGR2 be targeted for potential therapeutic applications in thrombocytopenia and cancer?

ASGR2's dual role in platelet homeostasis and its association with certain malignant phenotypes positions it as a potential therapeutic target for both hematological disorders and cancer. Research strategies for therapeutic development should consider:

• In thrombocytopenia associated with sepsis:

  • Selective inhibition of ASGR2 binding to desialylated platelets could reduce platelet clearance

  • Development of small molecule inhibitors targeting the carbohydrate recognition domain of ASGR2

  • Design of decoy ligands that competitively inhibit platelet binding

• In gastric cancer:

  • ASGR2 expression has been associated with malignant phenotypes in gastric cancer and may represent a specific biomarker for recurrence of certain gastric cancers

  • Targeted antibody-based therapies against tumor-expressed ASGR2

  • Development of diagnostic tools based on ASGR2 expression patterns

The therapeutic development pathway should include:

Research in these therapeutic areas should carefully consider the redundancy between ASGR1 and ASGR2 functions, as well as the potential consequences of modulating a receptor involved in glycoprotein homeostasis.

What are the optimal storage and handling conditions for recombinant ASGR2 proteins?

Maintaining the structural integrity and functional activity of recombinant ASGR2 proteins requires strict adherence to proper storage and handling protocols. Based on commercial recombinant ASGR2 Fc chimera proteins, the following guidelines should be observed:

• Reconstitution: Carefully reconstitute lyophilized protein using sterile buffer solutions, avoiding repeated freeze-thaw cycles which can compromise protein integrity.

• Storage temperature: Store the reconstituted protein at -80°C for long-term storage, with aliquots at -20°C for routine use. Avoid storing at 4°C for extended periods.

• Buffer compatibility: Recombinant ASGR2 functions optimally in physiological buffers (PBS with pH 7.2-7.4) supplemented with carrier proteins such as 0.1% BSA to prevent non-specific adsorption to tubes and surfaces.

• Activity preservation: The binding activity of ASGR2 to von Willebrand Factor can be preserved by the addition of stabilizing agents such as glycerol (10-15%) or low concentrations of non-ionic detergents (0.01-0.05% Tween-20).

• Quality control: Regularly verify protein integrity using SDS-PAGE analysis under both reducing and non-reducing conditions. Properly stored human ASGR2 Fc chimera should appear as distinct bands at the expected molecular weights (approximately 48 kDa for the monomeric form under reducing conditions) .

These handling precautions ensure that functional studies using recombinant ASGR2 proteins yield reliable and reproducible results by maintaining the native conformation and binding properties of the protein.

How can researchers assess the functional activity of recombinant ASGR2 preparations?

Verification of recombinant ASGR2 functional activity is essential prior to experimental use. A systematic approach to activity assessment includes:

• Binding assay with von Willebrand Factor: The gold standard for functional assessment involves measuring binding to human plasma von Willebrand Factor. Active recombinant human ASGR2 demonstrates binding with an ED50 of 0.15-0.9 μg/mL, while mouse ASGR2 shows binding with an ED50 of 0.05-0.6 μg/mL . Significant deviation from these values may indicate compromised protein activity.

• SDS-PAGE verification: Functional recombinant ASGR2 Fc chimera proteins should demonstrate the expected molecular weight profiles under both reducing conditions (62-81 kDa) and non-reducing conditions (120-160 kDa) . Different banding patterns may indicate protein degradation or improper folding.

• Glycan binding specificity: Functional ASGR2 should demonstrate preferential binding to desialylated glycans with terminal galactose residues. This can be assessed using glycan arrays or competitive binding assays with known ligands.

• Cell-based uptake assays: Active ASGR2, when expressed in appropriate cellular contexts, should mediate endocytosis of asialoglycoproteins. This can be monitored using fluorescently labeled asialofetuin and confocal microscopy or flow cytometry.

• Oligomerization assessment: Native PAGE or size exclusion chromatography can verify the ability of ASGR2 to form appropriate oligomeric structures, which are essential for its biological function.

These complementary approaches provide a comprehensive assessment of recombinant ASGR2 functional integrity, ensuring that subsequent experimental results accurately reflect the protein's native biological activities.

How should researchers address inconsistencies in ASGR2 molecular weight reporting?

The literature reveals discrepancies in the reported molecular weight of ASGR2, with values ranging from approximately 38 kDa to 48 kDa . These inconsistencies require careful consideration during experimental design and data interpretation. Researchers should address these variations through:

• Standardized reference samples: Include well-characterized recombinant ASGR2 standards in all electrophoretic analyses to provide internal calibration.

• Comprehensive documentation: Report the exact experimental conditions used for molecular weight determination, including buffer composition, reducing agents, and calibration standards.

• Consideration of post-translational modifications: Variations in glycosylation status can significantly impact apparent molecular weight. Enzymatic deglycosylation experiments can help distinguish the contribution of glycans to observed weight differences.

• Isoform specification: Clearly identify which of the four ASGR2 isoforms (a-d) is being analyzed, as alternative splicing creates variants with different molecular weights .

• Species-specific differences: Acknowledge and account for the molecular weight differences between human and rodent ASGR2 proteins when comparing across species (human ASGR2 shares 66% and 62% amino acid sequence identity with mouse and rat ASGR2, respectively) .

By systematically addressing these factors, researchers can minimize confusion and ensure more accurate and reproducible molecular characterization of ASGR2 across different experimental systems.

What approaches can resolve contradictory findings about ASGR2 expression patterns?

The discovery of ASGR2 expression in non-hepatic tissues such as peripheral blood monocytes challenges traditional assumptions about its tissue-specific expression pattern. To reconcile contradictory findings about ASGR2 expression, researchers should employ:

• Multi-modal detection strategies: Combine transcript analysis (RT-PCR, RNA-seq) with protein detection methods (Western blotting, immunohistochemistry, flow cytometry) to confirm expression at both RNA and protein levels.

• Nested PCR approach: For tissues with potentially low expression levels, use nested PCR with appropriate controls as described in the literature:

  • First round: 94°C for 30s; 60°C for 30s; 72°C for 1min 30s

  • Second round: 94°C for 30s; 60°C for 30s; 72°C for 1min

• Isoform-specific analysis: Design primers and antibodies that can distinguish between the different ASGR2 splice variants to determine if expression patterns vary by isoform.

• Single-cell analysis: Employ single-cell RNA-seq or flow cytometry to determine if ASGR2 expression is uniform or restricted to specific subpopulations within heterogeneous tissues.

• Functional validation: Confirm physiological relevance of detected expression through functional assays that demonstrate ASGR2-dependent activities in the tissue of interest.

These approaches provide a comprehensive framework for resolving discrepancies in ASGR2 expression data, advancing our understanding of its broader biological roles beyond hepatic tissues.